Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of US$2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase price of US$2.599 per share, which equals the public offering price per share of the common stock less the US$0.001 exercise price per share of each pre-funded warrant. The offering is expected to close on November 14, 2025, subject to the satisfaction of customary closing conditions.
Latham & Watkins LLP represents the underwriters in the offering, with a Capital Markets team led by New York partner Nathan Ajiashvili, with associates Sandy Kugbei and Jie Lin Nai, with assistance from Abdullah Khan.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.